27 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Amidino benzimidazole inhibitors of bacterial two-component systems.
The R. W. Johnson Pharmaceutical Research Institute
Alpha(2) adrenoceptor agonists as potential analgesic agents. 3. Imidazolylmethylthiophenes.
The R. W. Johnson Pharmaceutical Research Institute
N-(sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor.
The R. W. Johnson Pharmaceutical Research Institute
The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
The R. W. Johnson Pharmaceutical Research Institute
Design, synthesis, and biological activity of diiminoisoindolines as complement component 3a antagonists.
The R. W. Johnson Pharmaceutical Research Institute
1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.
The R. W. Johnson Pharmaceutical Research Institute
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
The R. W. Johnson Pharmaceutical Research Institute
Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor.
The R. W. Johnson Pharmaceutical Research Institute
Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide.
The R. W. Johnson Pharmaceutical Research Institute
Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.
The R. W. Johnson Pharmaceutical Research Institute
Novel heterocycles as selective alpha1-adrenergic receptor antagonists.
The R. W. Johnson Pharmaceutical Research Institute
Synthesis and erythropoietin receptor binding affinities of N,N-disubstituted amino acids.
The R. W. Johnson Pharmaceutical Research Institute
N-acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagoinists of the human neuropeptide Y Y5 receptor.
The R. W. Johnson Pharmaceutical Research Institute
Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists.
The R. W. Johnson Pharmaceutical Research Institute
Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
The R. W. Johnson Pharmaceutical Research Institute
Alpha(2) adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethyl-6,7-dihydro-thianaphthene as a high-affinity ligand for the alpha(2D) adrenergic receptor.
The R. W. Johnson Pharmaceutical Research Institute
1,3-Diarylcycloalkanopyrazoles and diphenyl hydrazides as selective inhibitors of cyclooxygenase-2.
The R. W. Johnson Pharmaceutical Research Institute
alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a high-affinity ligand for the alpha(2D) adrenergic receptor.
The R. W. Johnson Pharmaceutical Research Institute
alpha-Substituted N-(sulfonamido)alkyl-beta-aminotetralins: potent and selective neuropeptide Y Y5 receptor antagonists.
The R. W. Johnson Pharmaceutical Research Institute
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.
The R. W. Johnson Pharmaceutical Research Institute
Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1).
The R. W. Johnson Pharmaceutical Research Institute
N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.
The R. W. Johnson Pharmaceutical Research Institute
Pharmacological treatment of obesity: therapeutic strategies.
The R. W. Johnson Pharmaceutical Research Institute
6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.
The R. W. Johnson Pharmaceutical Research Institute
Alpha(2) adrenoceptor agonists as potential analgesic agents. 1. (Imidazolylmethyl)oxazoles and -thiazoles.
The R. W. Johnson Pharmaceutical Research Institute
Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria.
The R. W. Johnson Pharmaceutical Research Institute
